Optimization of second-generation antisense drugs: Going beyond generation 2.0

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 487-506

  Monia, Brett P ^a   Yu, Rosie Z ^a   Lima, Walt ^a   Siwkowski, Andrew ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865426451     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (31)

1. B. F. Baker, S. S. Lot, T. P. Condon, S. Cheng-Flournoy, E. A. Lesnik, H. M. Sasmor and C. F. Bennett; 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells; J Biol Chem; 272; 11994-2000; 1997.
2. Z. Dominski and R. Kole; Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides; Proc Natl Acad Sci USA; 90; 8673-8677; 1993.
3. J. G. Karras, R. A. McKay, T. Lu, N. M. Dean and B. P. Monia; Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells; Antisense Nucl Acid Drug Dev; 10; 347-357; 2000.
4. G. Meister and T. Tuschl; Mechanisms of gene silencing by double-stranded RNA; Nature; 431; 343-349; 2004.
5. H. Wu, W. F. Lima and S. T. Crooke; Properties of cloned and expressed human RNase H1; J Biol Chem; 274; 28270-28278; 1999.
6. B. F. Baker, L. Miraglia and C. H. Hagedorn; Modulation of eucaryotic initiation factor-4E binding to 5′-capped oligoribonucleotides by modified anti-sense oligonucleotides; J Biol Chem; 267; 11495-11499; 1992.
7. J. K. Taylor, Q. Q. Zhang, J. R. Wyatt and N. M. Dean; Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides; Nat Biotechnol; 17; 1097-10100; 1999.
8. J. Roberts, E. Palma, P. Sazani, H. Orum, M. Cho and R. Kole; Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice; Mol Ther; 14; 471-475; 2006.
9. T. A. Vickers, H. Zhang, M. J. Graham, K. M. Lemonidis, C. Zhao and N. M. Dean; Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide; J Immunol; 176; 3652-3661; 2006.
10. W. F. Lima, H. Wu and S. T. Crooke; Human RNases H; Methods Enzymol; 341; 430-440; 2001.
11. B. P. Monia, E. A. Lesnik, C. Gonzalez, W. F. Lima, D. McGee, C. J. Guinosso, A. M. Kawasaki, P. D. Cook and S. M. Freier; Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression; J Biol Chem; 268; 14514-14522; 1993.
12. C. F. Bennett; General pharmacology of phosphorothioate oligodeoxynucleotides; In Antisense Drug Technology: Principles, Strategies, and Applications; S. T. Crooke; ed. Marcel Dekker, Inc.; New York; 2001; pp. 291-318.
13. K. H. Altman, N. M. Dean, D. Fabbro, S. Freier, T. Geiger, R. Haner, D. Husken, P. Marting, B. P. Monia, M. Muller, F. Natt, P. Nicklin, J. Phillips, U. Pieles, H. Sasmor and H. E. Moser; Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals; Chimia; 50; 168-176; 1996.
14. B. P. Monia, J. F. Johnston, H. Sasmor and L. L. Cummins; Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras; J Biol Chem; 271; 14533-14540; 1996.
15. N. M. Dean, M. Butler, B. P. Monia and M. Manoharan; Pharmacology of 2′-O-(2′-Methoxyethoxy) Ethyl Modified Antisense Oligonucleotides; Antisense Drug Technology: Principles, Strategies and Applications; S. T. Crooke; Marcel Dekker, Inc.; New York; 2001; pp. 319-338.
16. W. F. Lima, J. G. Nichols, H. Wu, T. P. Prakash, M. T. Migawa, T. K. Wyrzykiewicz, B. Bhat and S. T. Crooke; Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis; J Biol Chem; 279; 36317-36326; 2004.
17. W. F. Lima, J. B. Rose, J. G. Nichols, H. Wu, M. T. Migawa, T. K. Wyrzykiewicz, G. Vasquez, E. E. Swayze and S. T. Crooke; The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis; Mol. Pharmacol; 71; 73-82; 2007.
18. H. Wu, W. F. Lima and S. T. Crooke; Molecular cloning and expression of cDNA for human RNase H; Antisense Nucl Acid Drug Dev; 8; 53-61; 1998.
19. H. Wu, W. F. Lima, H. Zhang, A. Fan, H. Sun and S. T. Crooke; Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs; J Biol Chem; 279; 17181-17189; 2004.
20. M. Butler, R. A. McKay, I. J. Popoff, W. A. Gaarde, D. Witchell, S. F. Murray, N. M. Dean, S. Bhanot and B. P. Monia; Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice; Diabetes; 51; 1028-1034; 2002.
21. R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan and A. A. Levin; Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats; J Pharmacol Exp Ther; 296; 890-897; 2001.
22. A. M. Siwkowski, L. A. Madge, S. Koo, E. L. McMillan, B. P. Monia, J. S. Pober and B. F. Baker; Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression; Mol Pharmacol; 66; 572-579; 2004.
23. M. Elchebly, P. Payette, E. Michaliszyn, W. Cromlish, S. Collins, A. L. Loy, D. Normandin, A. Cheng, J. Himms-Hagen, C. C. Chan, C. Ramachandran, M. J. Gresser, M. L. Tremblay and B. P. Kennedy; Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene; Science; 283; 1544-1548; 1999.
24. C. M. Rondinone, J. M. Trevillyan, J. Clampit, R. J. Gum, C. Berg, P. Kroeger, L. Frost, B. A. Zinker, R. Reilly, R. Ulrich, M. Butler, B. P. Monia, M. R. Jirousek and J. F. Waring; Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis; Diabetes; 51; 2405-2411; 2002.
25. B. A. Zinker, C. M. Rondinone, J. M. Trevillyan, R. J. Gum, J. E. Clampit, J. F. Waring, N. Xie, D. Wilcox, P. Jacobson, L. Frost, P. E. Kroeger, R. M. Reilly, S. Koterski, T. J. Opgenorth, R. G. Ulrich, S. Crosby, M. Butler, S. F. Murray, R. A. McKay, S. Bhanot, B. P. Monia and M. R. Jirousek; PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice; Proc Natl Acad Sci USA; 99; 11357-11362; 2002.
26. L. L. Kjems, S. Bhanot, J. D. Bradley, B. P. Monia, J. Kwoh and M. Wedel; Increased insulin sensitivity in humans by protein tyrosin IB (PTP1B) inhibition-evaluation of ISIS 113715, and antisense inhibition of PTP-1B; Diabetes; 54; A530; 2004.
27. S. Bhanot, L. M. Watts, K. W. Sloop, J. X. C. Cao, A. D. Showalter, M. D. Michael and B. P. Monia; Reduction of hepatic glucagon receptor expression with an optimized antisense oligonucleotide increased active GLP-1 levels in cynomolgus monkeys without pancreatic alpha cell expansion; Diabetes; 55; A326; 2006.
28. T. W. Kim, H. S. Rose, K. Kramer-Strickland, M. J. Graham, K. Subramaniam, R. M. Crooke, P. B. Lappin, G. S. Elliot, A. A. Levin and S. P. Henry; ISIS 326358 an antisense oligonucleotide targeted to ApoB reduces plasma LDL-C in a monkey model of hyperlipidemia; The Toxicologist; 90; 63; 2006.
29. W. F. Lima, J. B. Rose, J. G. Nichols, H. Wu, M. T. Migawa, T. K. Wyrzykiewicz, A. M. Siwkowski and S. T. Crooke; Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate; Mol. Pharmacol; 71; 83-91; 2007.
30. E. M. Wright; Renal Na(+)-glucose cotransporters; Am J Physiol Renal Physiol; 280; F10-F18; 2001.
31. S. T. Crooke, M. J. Graham, J. E. Zuckerman, D. Brooks, B. S. Conklin, L. L. Cummins, M. J. Greig, C. J. Guinosso, D. Kornbrust, M. Manoharan, H. M. Sasmor, T. Schleich, K. L. Tivel and R. H. Griffey; Pharmacokinetic properties of several novel oligonucleotide analogs in mice; J Pharmacol Exp Ther; 277; 923-937; 1996.